MedPath

Idivallathy Mezhugu-Vali Azhal Keel Vayu (Rheumatoid Arthritis)-A Pilot Study

Phase 2
Conditions
Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
Registration Number
CTRI/2022/02/040480
Lead Sponsor
ational Institute of Siddha
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Both sexes of age between 16 to 60.

Patient who meets the standard, European League against Rheumatism EULAR 2010 classification criteria.

A score >= 6 points is required for classification as definite RA.

Patients who are willing to attend OPD and IPD

Patients who are willing to undergo laboratory investigation.

Patient who are willing to sign the informed consent stating that he/ she will consciously stick to the treatment during 48 days but can stop out of the trail of his /her own conscious discretion.

Patients who are willing to follow diet restriction

Exclusion Criteria

Known C/O Other Auto immune diseases.

Patients receiving immunosuppressant, corticosteroids, antipsychotics, other arthritis medications including painkillers.

Known C/O Systemic Hypertension (SHT)

Known C/O Diabetes

Pregnant women.

Lactating women.

History of trauma

Known C/O Any other arthritis

Systemic complication of rheumatoid arthritis Patient.

Characteristic deformities of hand and feet in Rheumatoid Arthritis

Known C/O any other serious systemic illness like Cancer, Cardiac disease, Renal disease, Liver disorders, Neurological disorders.

Patients who had already participated in a new drug study in the past 3 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction of EULAR Score and Clinical Symptoms from Baseline Visit to End Visit. <br/ ><br>This Study Will Discover the Therapeutic Effectiveness of also Helps to Maximize the Quality of Life and Reduce the Burden of RA Patient. <br/ ><br>Timepoint: One Month - Screening <br/ ><br>Three Month - Enrollment <br/ ><br>One Month - Assessment <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To record if any adverse reactionTimepoint: four months;To Record If any Any Adverse ReactionTimepoint: Four month
© Copyright 2025. All Rights Reserved by MedPath